ChemPartner PharmaTech Co Ltd - Asset Resilience Ratio

Latest as of March 2026: 1.67%

ChemPartner PharmaTech Co Ltd (300149) has an Asset Resilience Ratio of 1.67% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See ChemPartner PharmaTech Co Ltd short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

CN¥33.99 Million

≈ $4.97 Million USD Cash + Short-term Investments

Total Assets

CN¥2.04 Billion

≈ $298.52 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2014–2025)

This chart shows how ChemPartner PharmaTech Co Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see 300149 current and non-current assets.

Liquid Assets Composition Over Time

This chart breaks down ChemPartner PharmaTech Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read 300149 total liabilities for a breakdown of total debt and financial obligations.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	CN¥0.00	0%
Short-term Investments	CN¥33.99 Million	1.67%
Total Liquid Assets	CN¥33.99 Million	1.67%

Asset Resilience Insights

Limited Liquidity: ChemPartner PharmaTech Co Ltd maintains only 1.67% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

ChemPartner PharmaTech Co Ltd Industry Peers by Asset Resilience Ratio

Compare ChemPartner PharmaTech Co Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Ligand Pharmaceuticals Incorporated NASDAQ:LGND	Biotechnology	16.06%
Halozyme Therapeutics Inc NASDAQ:HALO	Biotechnology	12.71%
Tubize-Fin BR:TUB	Biotechnology	2.50%
Beijing Tiantan Biological Products Corp Ltd SHG:600161	Biotechnology	8.08%
Rapport Therapeutics, Inc. Common Stock NASDAQ:RAPP	Biotechnology	81.15%
Galecto Inc NASDAQ:GLTO	Biotechnology	0.00%
Chengdu Kanghua Biological Products SHE:300841	Biotechnology	1.19%
Guangzhou Boji Medical and Biotechnological Co Ltd SHE:300404	Biotechnology	13.78%

Annual Asset Resilience Ratio for ChemPartner PharmaTech Co Ltd (2014–2025)

The table below shows the annual Asset Resilience Ratio data for ChemPartner PharmaTech Co Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	2.24%	CN¥45.57 Million ≈ $6.67 Million	CN¥2.03 Billion ≈ $297.48 Million	+2.19pp
2024-12-31	0.05%	CN¥1.05 Million ≈ $153.04K	CN¥2.00 Billion ≈ $292.05 Million	-0.04pp
2023-12-31	0.09%	CN¥2.21 Million ≈ $322.75K	CN¥2.43 Billion ≈ $356.22 Million	-0.36pp
2021-12-31	0.45%	CN¥18.98 Million ≈ $2.78 Million	CN¥4.22 Billion ≈ $617.17 Million	-0.04pp
2020-12-31	0.49%	CN¥20.08 Million ≈ $2.94 Million	CN¥4.12 Billion ≈ $603.12 Million	-1.22pp
2019-12-31	1.71%	CN¥64.40 Million ≈ $9.42 Million	CN¥3.77 Billion ≈ $551.34 Million	-10.21pp
2017-12-31	11.92%	CN¥124.34 Million ≈ $18.19 Million	CN¥1.04 Billion ≈ $152.65 Million	-27.54pp
2016-12-31	39.46%	CN¥313.00 Million ≈ $45.80 Million	CN¥793.16 Million ≈ $116.06 Million	-3.92pp
2015-12-31	43.39%	CN¥328.00 Million ≈ $48.00 Million	CN¥756.00 Million ≈ $110.63 Million	+38.26pp
2014-12-31	5.13%	CN¥38.00 Million ≈ $5.56 Million	CN¥741.13 Million ≈ $108.45 Million	--

pp = percentage points

About ChemPartner PharmaTech Co Ltd

SHE:300149 China Biotechnology

Market Cap

$650.71 Million

CN¥4.45 Billion CNY

Market Cap Rank

#11050 Global

#3068 in China

Share Price

CN¥8.93

Change (1 day)

-1.54%

52-Week Range

CN¥7.55 - CN¥13.97

All Time High

CN¥24.07